JP2016523847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523847A5 JP2016523847A5 JP2016518018A JP2016518018A JP2016523847A5 JP 2016523847 A5 JP2016523847 A5 JP 2016523847A5 JP 2016518018 A JP2016518018 A JP 2016518018A JP 2016518018 A JP2016518018 A JP 2016518018A JP 2016523847 A5 JP2016523847 A5 JP 2016523847A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- antibody
- composition according
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000025171 antigen binding proteins Human genes 0.000 claims 10
- 108091000831 antigen binding proteins Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 3
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 229940030627 lipid modifying agent Drugs 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- -1 fibrates Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832459P | 2013-06-07 | 2013-06-07 | |
| EP13305762.0 | 2013-06-07 | ||
| EP13305762.0A EP2810955A1 (en) | 2013-06-07 | 2013-06-07 | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| US61/832,459 | 2013-06-07 | ||
| US201361892215P | 2013-10-17 | 2013-10-17 | |
| US61/892,215 | 2013-10-17 | ||
| EP13306436.0 | 2013-10-18 | ||
| EP20130306436 EP2862877A1 (en) | 2013-10-18 | 2013-10-18 | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| US201461944855P | 2014-02-26 | 2014-02-26 | |
| US61/944,855 | 2014-02-26 | ||
| US201462002508P | 2014-05-23 | 2014-05-23 | |
| US62/002,508 | 2014-05-23 | ||
| PCT/US2014/041204 WO2014197752A1 (en) | 2013-06-07 | 2014-06-06 | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019033436A Division JP7112975B2 (ja) | 2013-06-07 | 2019-02-27 | Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523847A JP2016523847A (ja) | 2016-08-12 |
| JP2016523847A5 true JP2016523847A5 (enExample) | 2017-07-20 |
Family
ID=52008606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518018A Pending JP2016523847A (ja) | 2013-06-07 | 2014-06-06 | Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10494442B2 (enExample) |
| EP (1) | EP3004171B1 (enExample) |
| JP (1) | JP2016523847A (enExample) |
| KR (1) | KR20160024906A (enExample) |
| CN (2) | CN111920954A (enExample) |
| AU (2) | AU2014274844B2 (enExample) |
| CA (1) | CA2914721A1 (enExample) |
| EA (1) | EA201592267A1 (enExample) |
| HK (1) | HK1222865A1 (enExample) |
| MX (1) | MX2015016887A (enExample) |
| TW (2) | TW202021614A (enExample) |
| WO (1) | WO2014197752A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| MX385311B (es) | 2011-01-28 | 2025-03-18 | Sanofi Biotechnology | Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| KR20160024906A (ko) * | 2013-06-07 | 2016-03-07 | 사노피 바이오테크놀로지 | Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법 |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| EP3169710A1 (en) * | 2014-07-14 | 2017-05-24 | Amgen Inc. | Crystalline antibody formulations |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| US10683366B2 (en) | 2015-09-25 | 2020-06-16 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of atherosclerosis |
| CN105214087B (zh) | 2015-10-29 | 2017-12-26 | 陈敏 | Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用 |
| HRP20230992T1 (hr) * | 2016-02-17 | 2023-12-08 | Regeneron Pharmaceuticals, Inc. | Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3 |
| MX2018010401A (es) | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| CA3026823A1 (en) * | 2016-06-24 | 2017-12-28 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-ｐｃｓｋ９ 항체 |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Limited | peptídeo |
| JP7444858B2 (ja) * | 2018-09-05 | 2024-03-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 喘息及びアレルギー性疾患を処置するための方法及び組成物 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| WO2021058597A1 (en) * | 2019-09-24 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject is at risk of developing arterial plaques |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP2000509018A (ja) | 1996-03-26 | 2000-07-18 | イーライ・リリー・アンド・カンパニー | 肥満タンパク質製剤 |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
| US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| DE69900746T2 (de) | 1998-01-30 | 2002-08-14 | Scios Inc., Mountain View | Gesteuerte verabreichung von peptiden oder proteinen |
| EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
| US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
| US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
| AU2001241461A1 (en) | 2000-02-07 | 2001-08-14 | Millennium Pharmaceuticals, Inc. | Narc-1, novel subtilase-like homologs |
| AU2001290846B2 (en) | 2000-09-08 | 2006-02-02 | Massachusetts Institute Of Technology | G-CSF analog compositions and methods |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20110313024A1 (en) | 2004-08-20 | 2011-12-22 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
| DK2021472T3 (da) | 2006-05-05 | 2011-09-19 | Isis Pharmaceuticals Inc | Forbindelser og fremgangsmåder til modulering af genekspression |
| ES2366973T3 (es) | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimiento para modular la expresión génica. |
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| SI2944306T1 (sl) | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2083860A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | PCSK9 ANTAGONISTS |
| WO2008057457A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2106261A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
| WO2008057459A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| BRPI0810551A2 (pt) | 2007-04-13 | 2019-09-03 | Novartis Ag | moléculas e métodos para modulação da pró-proteína convertase subtilisina/quexina tipo 9 (pcsk9) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| KR20100091191A (ko) | 2007-10-26 | 2010-08-18 | 쉐링 코포레이션 | 항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법 |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| CA2736864C (en) | 2008-09-19 | 2020-10-13 | Pfizer Inc. | Stable liquid antibody formulation |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| AU2010260148A1 (en) | 2009-06-15 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
| CA2764180A1 (en) | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| US20110009628A1 (en) | 2009-07-08 | 2011-01-13 | Haiyan Liu | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same |
| US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
| WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
| EP2483682A1 (en) | 2009-10-02 | 2012-08-08 | INSERM - Institut National de la Santé et de la Recherche Médicale | Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event |
| CN102596249A (zh) | 2009-10-30 | 2012-07-18 | 默沙东公司 | Ax1和ax189 pcsk9拮抗剂和变体 |
| IN2012DN03824A (enExample) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| CN106267189B (zh) | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | 含有抗白介素-4受体(il-4r)的抗体的稳定制剂 |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| US9518132B2 (en) | 2010-11-09 | 2016-12-13 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
| BR112013015687A2 (pt) | 2010-12-22 | 2016-10-11 | Genentech Inc | anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito |
| MX385311B (es) | 2011-01-28 | 2025-03-18 | Sanofi Biotechnology | Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes. |
| KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
| AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
| BR112014000392A2 (pt) | 2011-07-14 | 2017-02-21 | Pfizer | tratamento com anticorpos anti-pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| EP2882778B1 (en) | 2012-08-13 | 2018-04-11 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP2703008A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
| EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| KR20160024906A (ko) | 2013-06-07 | 2016-03-07 | 사노피 바이오테크놀로지 | Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법 |
| ES2914978T3 (es) | 2013-10-11 | 2022-06-20 | Sanofi Biotechnology | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| EP3104879A2 (en) | 2014-02-14 | 2016-12-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy |
| US20150283236A1 (en) | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| PL3119810T3 (pl) | 2014-03-17 | 2024-07-15 | Sanofi Biotechnology | Sposoby obniżania ryzyka sercowo-naczyniowego |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| JP6912374B2 (ja) | 2014-07-16 | 2021-08-04 | サノフィ・バイオテクノロジー | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
-
2014
- 2014-06-06 KR KR1020167000010A patent/KR20160024906A/ko not_active Ceased
- 2014-06-06 WO PCT/US2014/041204 patent/WO2014197752A1/en not_active Ceased
- 2014-06-06 HK HK16111037.4A patent/HK1222865A1/zh unknown
- 2014-06-06 CA CA2914721A patent/CA2914721A1/en not_active Abandoned
- 2014-06-06 EA EA201592267A patent/EA201592267A1/ru unknown
- 2014-06-06 MX MX2015016887A patent/MX2015016887A/es unknown
- 2014-06-06 TW TW108126132A patent/TW202021614A/zh unknown
- 2014-06-06 CN CN202010812439.XA patent/CN111920954A/zh active Pending
- 2014-06-06 EP EP14737087.8A patent/EP3004171B1/en active Active
- 2014-06-06 US US14/896,196 patent/US10494442B2/en active Active
- 2014-06-06 AU AU2014274844A patent/AU2014274844B2/en not_active Ceased
- 2014-06-06 TW TW103119641A patent/TW201534324A/zh unknown
- 2014-06-06 CN CN201480032506.9A patent/CN105705521A/zh active Pending
- 2014-06-06 JP JP2016518018A patent/JP2016523847A/ja active Pending
-
2018
- 2018-01-18 US US15/874,807 patent/US20180244801A1/en not_active Abandoned
-
2019
- 2019-07-08 US US16/505,074 patent/US10995150B2/en active Active
-
2020
- 2020-02-19 AU AU2020201191A patent/AU2020201191A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520616A5 (enExample) | ||
| HRP20241450T1 (hr) | Postupci za smanjivanje razina lipoproteina(a) putem primjene inhibitora proproteinske konvertaze suptilizin keksin 9 (pcsk9) | |
| JP2019514907A5 (enExample) | ||
| JP2016538248A5 (enExample) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2014516953A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| JP2016515134A5 (enExample) | ||
| Taraseviciene-Stewart et al. | Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2012021001A5 (enExample) | ||
| JP2016522211A5 (enExample) | ||
| JP2022116083A5 (enExample) | ||
| JP2017515893A5 (enExample) | ||
| JP2018536710A5 (enExample) | ||
| FI3666797T3 (fi) | Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9) | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| JP2014502955A5 (enExample) | ||
| RU2018120599A (ru) | Лечение смешанной дислипидемии | |
| JP2013023499A5 (enExample) |